Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2025 13:34 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The...
June 17, 2025 11:37 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
June 16, 2025 09:28 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...
June 15, 2025 05:00 ET | Source: Genmab A/S

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with rituximab, ifosfamide, carboplatin, and...
June 12, 2025 13:08 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; June 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to...
June 10, 2025 07:23 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 10, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...
June 02, 2025 14:30 ET | Source: Genmab A/S

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Media ReleaseCOPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S®) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete...
June 02, 2025 08:03 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...
May 27, 2025 09:55 ET | Source: Genmab A/S

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; May 27, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the 46th Goldman Sachs...
May 26, 2025 08:30 ET | Source: Genmab A/S

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 26, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...